Here's how to play the stock right now.
Shares of the maker of Botox are struggling despite its latest results exceeding expectations.
Time could run out before Larry Culp can complete his turnaround plan at GE.
GE stock hasn't solved its free cash flow conundrum, and might not for some time, says a key analyst.
The stock of the maker of life sciences research technology is trading in the low teens, but a key chart indicates no price resistance until the low $20s.
David Tepper's Appaloosa LP renews calls for changes at the top.
A key chart suggests further gains in the chemical giant are possible, but be aware that it could explore lower levels of October again.
Biogen shares rose 15% Friday following upbeat results from an Alzheimer's drug test.
What was once a red and blue issue has now attracted a growing set of proponents from both sides of the aisle.
Novartis agreed to acquire AveXis for $8.7 billion on Monday. TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer reacts.